Literature DB >> 21685049

Enhancing the rate of scaffold discovery with diversity-oriented prioritization.

S Joshua Swamidass1, Bradley T Calhoun, Joshua A Bittker, Nicole E Bodycombe, Paul A Clemons.   

Abstract

MOTIVATION: In high-throughput screens (HTS) of small molecules for activity in an in vitro assay, it is common to search for active scaffolds, with at least one example successfully confirmed as an active. The number of active scaffolds better reflects the success of the screen than the number of active molecules. Many existing algorithms for deciding which hits should be sent for confirmatory testing neglect this concern.
RESULTS: We derived a new extension of a recently proposed economic framework, diversity-oriented prioritization (DOP), that aims-by changing which hits are sent for confirmatory testing-to maximize the number of scaffolds with at least one confirmed active. In both retrospective and prospective experiments, DOP accurately predicted the number of scaffold discoveries in a batch of confirmatory experiments, improved the rate of scaffold discovery by 8-17%, and was surprisingly robust to the size of the confirmatory test batches. As an extension of our previously reported economic framework, DOP can be used to decide the optimal number of hits to send for confirmatory testing by iteratively computing the cost of discovering an additional scaffold, the marginal cost of discovery. CONTACT: swamidass@wustl.edu SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Entities:  

Mesh:

Year:  2011        PMID: 21685049      PMCID: PMC3150035          DOI: 10.1093/bioinformatics/btr369

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  25 in total

1.  Assessment of the consistency of medicinal chemists in reviewing sets of compounds.

Authors:  Michael S Lajiness; Gerald M Maggiora; Veerabahu Shanmugasundaram
Journal:  J Med Chem       Date:  2004-09-23       Impact factor: 7.446

Review 2.  Design and analysis of experiments with high throughput biological assay data.

Authors:  David M Rocke
Journal:  Semin Cell Dev Biol       Date:  2004-12       Impact factor: 7.727

Review 3.  Similarity-based virtual screening using 2D fingerprints.

Authors:  Peter Willett
Journal:  Drug Discov Today       Date:  2006-10-20       Impact factor: 7.851

4.  Enrichment of high-throughput screening data with increasing levels of noise using support vector machines, recursive partitioning, and laplacian-modified naive bayesian classifiers.

Authors:  Meir Glick; Jeremy L Jenkins; James H Nettles; Hamilton Hitchings; John W Davies
Journal:  J Chem Inf Model       Date:  2006 Jan-Feb       Impact factor: 4.956

5.  The minimum significant ratio: a statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies.

Authors:  Brian J Eastwood; Mark W Farmen; Philip W Iversen; Trelia J Craft; Jeffrey K Smallwood; Kim E Garbison; Neil W Delapp; Gerald F Smith
Journal:  J Biomol Screen       Date:  2006-02-20

6.  An efficient method for the detection and elimination of systematic error in high-throughput screening.

Authors:  Vladimir Makarenkov; Pablo Zentilli; Dmytro Kevorkov; Andrei Gagarin; Nathalie Malo; Robert Nadon
Journal:  Bioinformatics       Date:  2007-04-26       Impact factor: 6.937

7.  Optimization of CAMD techniques 3. Virtual screening enrichment studies: a help or hindrance in tool selection?

Authors:  Andrew C Good; Tudor I Oprea
Journal:  J Comput Aided Mol Des       Date:  2008-01-09       Impact factor: 3.686

8.  Enhanced HTS hit selection via a local hit rate analysis.

Authors:  Bruce A Posner; Hualin Xi; James E J Mills
Journal:  J Chem Inf Model       Date:  2009-10       Impact factor: 4.956

Review 9.  What do we know and when do we know it?

Authors:  Anthony Nicholls
Journal:  J Comput Aided Mol Des       Date:  2008-02-06       Impact factor: 3.686

10.  ChemBank: a small-molecule screening and cheminformatics resource database.

Authors:  Kathleen Petri Seiler; Gregory A George; Mary Pat Happ; Nicole E Bodycombe; Hyman A Carrinski; Stephanie Norton; Steve Brudz; John P Sullivan; Jeremy Muhlich; Martin Serrano; Paul Ferraiolo; Nicola J Tolliday; Stuart L Schreiber; Paul A Clemons
Journal:  Nucleic Acids Res       Date:  2007-10-18       Impact factor: 16.971

View more
  5 in total

1.  Managing missing measurements in small-molecule screens.

Authors:  Michael R Browning; Bradley T Calhoun; S Joshua Swamidass
Journal:  J Comput Aided Mol Des       Date:  2013-04-13       Impact factor: 3.686

2.  Utility-aware screening with clique-oriented prioritization.

Authors:  S Joshua Swamidass; Bradley T Calhoun; Joshua A Bittker; Nicole E Bodycombe; Paul A Clemons
Journal:  J Chem Inf Model       Date:  2011-12-20       Impact factor: 4.956

3.  A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes.

Authors:  Matthew K Matlock; Abhik Tambe; Jack Elliott-Higgins; Ronald N Hines; Grover P Miller; S Joshua Swamidass
Journal:  Chem Res Toxicol       Date:  2019-07-29       Impact factor: 3.739

4.  An informatic pipeline for managing high-throughput screening experiments and analyzing data from stereochemically diverse libraries.

Authors:  Carol A Mulrooney; David L Lahr; Michael J Quintin; Willmen Youngsaye; Dennis Moccia; Jacob K Asiedu; Evan L Mulligan; Lakshmi B Akella; Lisa A Marcaurelle; Philip Montgomery; Joshua A Bittker; Paul A Clemons; Stephen Brudz; Sivaraman Dandapani; Jeremy R Duvall; Nicola J Tolliday; Andrea De Souza
Journal:  J Comput Aided Mol Des       Date:  2013-04-13       Impact factor: 3.686

5.  Bigger data, collaborative tools and the future of predictive drug discovery.

Authors:  Sean Ekins; Alex M Clark; S Joshua Swamidass; Nadia Litterman; Antony J Williams
Journal:  J Comput Aided Mol Des       Date:  2014-06-19       Impact factor: 3.686

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.